Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $120.3 million.

  • Kymera Therapeutics' Cash & Equivalents rose 2.02% to $112.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.9 million, marking a year-over-year increase of 2.02%. This contributed to the annual value of $120.3 million for FY2024, which is 9.36% up from last year.
  • Per Kymera Therapeutics' latest filing, its Cash & Equivalents stood at $120.3 million for FY2024, which was up 9.36% from $110.0 million recorded in FY2023.
  • Kymera Therapeutics' 5-year Cash & Equivalents high stood at $120.3 million for FY2024, and its period low was $31.0 million during FY2020.
  • For the 3-year period, Kymera Therapeutics' Cash & Equivalents averaged around $99.5 million, with its median value being $110.0 million (2023).
  • Per our database at Business Quant, Kymera Therapeutics' Cash & Equivalents plummeted by 59.21% in 2020 and then skyrocketed by 60.78% in 2023.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Cash & Equivalents stood at $31.0 million in 2020, then soared by 54.74% to $48.0 million in 2021, then surged by 42.56% to $68.4 million in 2022, then soared by 60.78% to $110.0 million in 2023, then climbed by 9.36% to $120.3 million in 2024.